Interested in Bringing a Group to Café? Schedule a Group Visit

LOCATION
Venture Café Cambridge
1 Broadway,5th Floor
Cambridge, MA 02142

DATE
April 11, 2019

TIME
3:00 – 8:30 PM

 

RSVP
HERE

ABOUT THIS EVENT

The Future of Medicine: Biomedical Innovation in Boston & Japan

Solving some of the world’s most challenging problems requires collaboration across industry and across national borders. Takeda Pharmaceutical Company believes in empowering high-potential startups to share knowledge and resources with each other to further biomedical research. Accordingly, the “Shonan iPark”, an open innovation facility for biotech companies, was launched in 2018 to encourage international collaboration through scientific innovation.

Join us April 11th at Venture Café to learn about cutting-edge research in iPS cell technology coming out of the iPark, connect with international biotech innovators, and discuss the future of drug development. Takeda representatives will also be onsite to support high-potential startups explore business opportunities in Japan and other parts of Asia.

 

OUR SPONSORS

PARTICIPATING COMPANIES

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

EVENT SCHEDULE

Blank
FLASH TALKS: INTEGRATED DRUG DISCOVERY SERVICE FOR BETTER TARGET AND BETTER MOLECULE (5:00 PM - 5:45 PM)

FLASH TALKS: INTEGRATED DRUG DISCOVERY SERVICE FOR BETTER TARGET AND BETTER MOLECULE (5:00 PM – 5:45 PM)

Having confidence with “Better target” and discovering “Better molecule” are critical keys to advance at an early stage of drug discovery. The session tells you how getting access to these two Betters from the aspect of Axcelead capability and technology (e.g. leveraging bioinformatics and omics data & >90% HTS hit rate with an extensive compound library and outstanding experience) .

(Room: Octave)

 

Kazuyoshi Aso,Senior Director, Head of Chemistry
Axcelead Drug Discovery Partners, Inc,

Kazuyoshi Aso, Senior Director, Head of Chemistry, Axcelead Drug Discovery Partners, Inc

Kazuyoshi Aso, PhD, Senior Director, Head of Chemistry, joined Axcelead Drug Discovery Partners in 2017. He has over 25 years of experience across all stages of drug discovery. Prior to joining Axcelead, Kazu was at Takeda Pharmaceutical Company, where he led and contributed to multidisciplinary drug discovery teams targeting diseases in the CNS, oncology, cardiovascular, and inflammation therapeutic areas. He also has international leadership experience from 2014 to 2017. He was at Tri-Institutional Therapeutic Discovery Institute (Tri-I TDI), where he directed drug discovery teams and managed attendant business issues.

Tish Scolnik,CEO

Tomoyuki Fujisawa, Managing Director, Chief Fund Manager of Healthcare Investment
Whiz Partners

Tomoyuki Fujisawa, Managing Director, Chief Fund Manager of Healthcare Investment, Whiz Partners

As a founder of Takeda Venture Inc.(TVI), and the global head of Takeda’s product licensing and research alliance group for 10 years, Tomo was deeply involved most of Takeda’s business transactions from 2001 to 2011. Since 2012, as Managing Director, Chief Fund Manager of Healthcare Investment, Whiz Partners, Tomo established 4 healthcare funds and raised over US$ 300 million and more than 10 investments made mainly Japanese publicly traded companies.

DEMO (5:00 PM - 8:00 PM)

DEMO (5:00 PM – 8:00 PM)

 

ROUND ROBIN: REGENERATION OF CELLS & REPROGRAMMING THE FUTURE (5:30 PM - 6:30 PM)
ROUND ROBBIN: Regeneration of Cells & Reprogramming the Future (5:30 PM – 6:30 PM)

 

T-CiRA, joint research program with Takeda and the Center for iPS Cell Research and Application (CiRA) in Kyoto University and Takeda, is a prime example of how Takeda is embracing open innovation, inspirations and insights of external partners. Making advancements in this interdisciplinary field requires collaboration, across industry and across national borders. Join us on April 11th at Venture Café to learn about cutting-edge research in iPS cell technology, connect with international biotech innovators, and discuss the future of cell therapies. We’d like to call for collaborators to bring definitive therapies as iPSC-derived pancreatic islet cells and cardiomyocytes for the patients.

(Room: Havana)

 

Maria Forney,Director, Oracle Global Startup Ecosystem

Dan Curran, Head of the Rare Diseases Therapeutic Area Unit
Takeda Pharmaceutical Company Ltd.

Dan Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda Pharmaceutical Company Ltd.

Dr. Daniel Curran is the designate Head of the Rare Diseases Therapeutic Area Unit (TAU) at Takeda Pharmaceutical Company Ltd. In this role, he will lead Takeda’s efforts to unlock innovation and deliver transformative medicines in the areas of rare immunology, rare hematology, lysosomal storage disorders, rare genetic and metabolic diseases, and other disease areas. Previously, Dr. Curran served as Head of Takeda’s Center for External Innovation (CEI). In this role, he and his team have diversified Takeda’s pipeline, completed approximately 150 transactions and invested $1.5 billion in capital in external relationships and investments over a period of three years. In addition, Dr. Curran has been the interim leader of Takeda-CiRA collaboration in Takeda, a joint research program with Kyoto University’s Center for iPS Cell Research Application.

Maria Forney,Director, Oracle Global Startup Ecosystem

Taro Toyoda,
T-CiRA (Joint Program of Takeda and Kyoto University)

Taro Toyoda

2006-2010, post-doc in Joslin Diabetes Center, affiliated with Harvard Medical School in Boston.
2010-2015, associate professor, in Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan.
2015-, junior associate professor, in Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan.
2016-, principal investigator in CiRA-Takeda joint program “T-CiRA.”

Maria Forney,Director, Oracle Global Startup Ecosystem

Yoshinori Yoshida,
T-CiRA (Joint Program of Takeda and Kyoto University)

Yoshinori Yoshida, T-CiRA (Joint Program of Takeda and Kyoto University)

Yoshinori started his career as a cardiovascular physician in 1997. In 2008, he joined Yamanaka lab in Kyoto University as a postdoc after obtaining PhD degree from Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University. He conducted research to elucidate the mechanisms of iPS cell generation and cardiomyocyte differentiation. Yoshinori became a principal investigator in Center for iPS Cell Research and Application (CiRA) in 2009, his research focused on development of myocardial regenerative medicine and cardiac disease study using iPS cells.
In 2016, Yoshinori joined T-CiRA program, a collaborative research project between CiRA and Takeda, as a principal investigator of Cardiomyocyte Project. The Cardiomyocyte Project aims to establish cell transplantation therapy using iPS cell-derived cardiomyocytes for heart failure patients and develop a new drug for hypertrophic cardiomyopathy using iPS cell-based drug discovery platform.

FLASH TALKS: INTEGRATED DRUG DISCOVERY SERVICE FOR BETTER TRANSLATION (6:00 PM - 6:45 PM)

FLASH TALKS: INTEGRATED DRUG DISCOVERY SERVICE FOR BETTER TRANSLATION (6:00 PM – 6:45 PM)

Ensuring a steady implementation of preclinical studies followed by IND submission is highly relied on the experience and knowledge toward successful clinical trials. The session tells you what Axcelead can bring to you and differentiates from the others (e.g. contribution to 100+ IND and 20+ NDA projects spanning various TAs, partnering “modeling & simulation” with LAP&P)

(Room: Octave)

 

Yoshinori Ikeura, CEO
Axcelead Drug Discovery Partners (AXL)

Yoshinori Ikeura, CEO, Axcelead Drug Discovery Partners (AXL)

Yoshinori Ikeura is CEO of Axcelead Drug Discovery Partners (AXL). He worked for Takeda Pharmaceutical Company Limited for over 30 years in executive roles ranging from Head of the Inflammation Drug Discovery Unit to Shonan Site Head. Since 2017, he has been CEO of AXL. He also participated in social activities as Vice-Chairman of the JPMA R&D Committee, etc. He is passionate about supporting people to create innovative medicine and contributing global healthcare.

Tish Scolnik,CEO

Victor Stone,
Drug Discovery Gateway Fund by Whiz Partners

Victor Stone, Drug Discovery Gateway Fund by Whiz Partners

Victor Stone M.D. (Ishii, Yoshihide) is a Japanese born, American trained physician currently serving as a Life Science Private Equity investor at Whiz Partners. He received his medical training at Jefferson Medical College in Philadelphia, and served in the United States Marine Corps as a Naval Flight Surgeon. His duties included multiple combat tours to the middle east and hospital administration. After military service, he attended business school in Boston, and currently serves dual roles as both entrepreneur of tech start-ups and as Life Science investor.

PITCH: REGENERATIVE MEDICINE PITCH COMPETITION (6:45 PM - 8:00 PM)

PITCH: REGENERATIVE MEDICINE PITCH COMPETITION (6:45 PM – 8:00 PM)

In this session, three Boston-based startups with cutting-edge technologies for regenerative medicine research will be awarded round-trip tickets to Japan and other prizes. Regenerative medicine combines knowledge and technological advancements in genetics, biology, chemistry, engineering, robotics, and computer science. Medical researchers around the world are starting to see the potential in this new field, especially in Japan. Dr. Shinya Yamanaka received the Nobel Prize for iPS research in 2012, and since then the national government has changed legislation regulating research in this field to promote the development of new practical applications.

(Room: Havana)

 

Maria Forney,Director, Oracle Global Startup Ecosystem

Toshio Fujimoto, General Manager
Shonan Health Innovation Park (iPark)

Presentation: Advancements in Regenerative Medicine – perspectives from Japan. 

Toshio Fujimoto, General Manager, Shonan Health Innovation Park (iPark)

Toshio Fujimoto, MD, MBA, is the General Manager of Shonan Health Innovation Park (iPark), a science park launched by Takeda Pharmaceutical Company Ltd in Shonan, Japan in April 2018. Prior to joining Shonan iPark, Dr. Fujimoto held positions with increasing responsibility at Eli Lilly Japan. Most recently he was Vice President of the Medicine Development Unit, where he oversaw the R&D Management function in Japan. Earlier in his career, he worked as a sergeon at several hospitals in Japan, U.S., and Germany for over 10 years.

Tish Scolnik,CEO

Tomoyuki Fujisawa, Managing Director, Chief Fund Manager of Healthcare Investment
Whiz Partners

Tomoyuki Fujisawa, Managing Director, Chief Fund Manager of Healthcare Investment

As a founder of Takeda Venture Inc.(TVI), and the global head of Takeda’s product licensing and research alliance group for 10 years, Tomo was deeply involved most of Takeda’s business transactions from 2001 to 2011. Since 2012, as Managing Director, Chief Fund Manager of Healthcare Investment, Whiz Partners, Tomo established 4 healthcare funds and raised over US$ 300 million and more than 10 investments made mainly Japanese publicly traded companies.

Aagya Mathur,CEO & Co-Founder,Aavia

Nenad Grmusa, Head of the Center for External Innovation
Takeda Pharmaceutical Company Ltd.

Nenad Grmusa, Head of the Center for External InnovationTakeda Pharmaceutical Company Ltd.

Nenad Grmusa is the Head of the Center for External Innovation (CEI) at Takeda Pharmaceutical Company Ltd. and a member of the R&D Management Committee (RMC). In his role, he assumes oversight of all external research and development activities including: strategic venture investments, academic alliances, spinouts and merger and acquisitions. He is also responsible for the creation of innovative drug discovery business development and venture investment models and divestiture strategies for non-core assets.

FLASH TALKS: REINVENTING SMALL MOLECULE DEVELOPMENT THROUGH UNSTRUCTURED PROTEIN (7:00 PM - 7:45 PM)

FLASH TALKS: REINVENTING SMALL MOLECULE DEVELOPMENT THROUGH UNSTRUCTURED PROTEIN (7:00 PM – 7:45 PM)

We have recently created compound library which targets unstructured protein associated with transcriptional factors within the cell. Compounds has three dimensional flexibility allowing precise mimicking of unstructured domain of target protein. Precise mimicking allows efficacy, safety and specificity.

(Room: Octave)

 

Fumito Aranami, Manager of business development
Oita University Institute of Advanced Medicine, Inc.

Fumito Aranami, Manager of business development, Oita University Institute of Advanced Medicine, Inc.

Experienced Business with a demonstrated history of working in the Shionogi since 2010. Transferred to IAM as Business Development Manager from 2018. Skilled in Business Development. Strong professional with a Doctor of Philosophy (Ph.D.) focused in Nutrition Sciences from The University of Tokushima.

SPEAKERS

Toshio Fujimoto

Shonan Health Innovation Park (iPark)

Tomoyuki Fujisawa

Whiz Partners

Nenad Grmusa

Takeda Pharmaceutical Company Ltd.

Dan Curran

Takeda Pharmaceutical Company Ltd.

Kazuyoshi Aso

Axcelead Drug Discovery Partners, Inc

Taro Toyoda

T-CiRA (Joint Program of Takeda and Kyoto University)

Yoshinori Yoshida

T-CiRA (Joint Program of Takeda and Kyoto University)

Yoshinori Ikeura

Axcelead Drug Discovery Partners (AXL)

Victor Stone

Whiz Partners

Fumito Aranami

Oita University Institute of Advanced Medicine, Inc.

ABOUT OUR SPONSORS

 

Takeda Pharmaceutical Company is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. Takeda Pharmaceutical Company launched “Shonan iPark” open to the public, transforming its research site to become Japan`s leading innovation engine in April 2018. More than 35 companies including big pharma, biotech, service provider and academia have joined iPark, and many more are expected to be recruited from among leading biotech companies from all over the word to enhance scientific innovation.

Social Share Buttons and Icons powered by Ultimatelysocial